NASDAQ · Financial Statements

Integra LifeSciences Holdings Corporation (IART) Revenue, Earnings & Financial Statements

$13.55 NASDAQ: IART Market Cap $1.05B

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Integra LifeSciences Holdings Corporation most recently reported annual revenue of $1.6B, a net loss of $516.0M. Revenue grew at an average annual rate of 3.6% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Integra LifeSciences Holdings Corporation: Revenue rose from $992.0M in 2016 to $1.6B in 2025, a change of +64.8% over 9 years; net profit was positive in 8 of 10 reported years; operating margin moved from 11.6% to 4.2%, a shift of -7.5 percentage points; the most recent year shows a net loss of $516.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$992.0M$1.2B$1.5B$1.5B$1.4B$1.5B$1.6B$1.5B$1.6B$1.6B
Operating Expenses$877.0M$1.1B$1.4B$1.4B$1.2B$1.3B$1.3B$1.4B$1.6B$1.6B
Operating Profit$115.0M$45.0M$111.0M$94.0M$151.0M$197.0M$239.0M$112.0M$28.0M$68.0M
Operating Margin11.6%3.8%7.5%6.2%11.0%12.8%15.3%7.2%1.8%4.2%
Other Income−$25.0M−$33.0M−$54.0M−$34.0M−$58.0M$17.0M−$25.0M−$30.0M−$47.0M−$632.0M
Interest$26.0M$35.0M$65.0M$54.0M$72.0M$50.0M$50.0M$51.0M$71.0M$86.0M
Depreciation$73.0M$89.0M$111.0M$109.0M$116.0M$120.0M$118.0M$124.0M$141.0M$152.0M
Profit Before Tax$90.0M$11.0M$57.0M$60.0M$94.0M$215.0M$214.0M$81.0M−$18.0M−$564.0M
Tax rate (%)17.5%-468.7%-5.9%16.5%-43.2%21.2%15.6%16.4%61.9%8.3%
Net Profit$75.0M$65.0M$61.0M$50.0M$134.0M$169.0M$181.0M$68.0M−$7.0M−$516.0M
EPS$0.94$0.82$0.72$0.58$1.57$1.98$2.16$0.84−$0.09−$6.73

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$397.0M$369.0M$418.0M$381.0M$443.0M$383.0M$416.0M$402.0M$435.0M$392.0M$419.0M$411.0M
Operating Expenses$361.0M$365.0M$421.0M$389.0M$407.0M$398.0M$928.0M$362.0M−$121.0M$352.0M$399.0M$392.0M
Operating Profit$36.0M$4.0M−$3.0M−$8.0M$36.0M−$15.0M−$513.0M$40.0M$556.0M$40.0M$19.0M$19.0M
Operating Margin9.1%1.1%-0.7%-2.1%8.1%-4.0%-123.4%10.0%127.9%10.2%4.6%4.6%
Interest$14.0M$14.0M$19.0M$19.0M$19.0M$20.0M$21.0M$23.0M$24.0M$27.0M$23.0M$23.0M
Profit Before Tax$29.0M−$5.0M−$15.0M−$20.0M$23.0M−$30.0M−$531.0M−$7.0M$4.0M−$2.0M$5.0M$16.0M
Tax rate (%)31.3%37.3%18.3%47.5%13.8%15.8%8.8%20.8%139.5%-91.7%5.5%5.2%
Net Profit$20.0M−$3.0M−$12.0M−$11.0M$19.0M−$25.0M−$484.0M−$5.0M−$2.0M−$5.0M$4.0M$15.0M
EPS$0.25−$0.04−$0.16−$0.14$0.25−$0.33−$6.33−$0.07−$0.02−$0.06$0.06$0.19

Over the 10 years reported for Integra LifeSciences Holdings Corporation, borrowings increased from $665.0M in 2016 to $2.0B in 2025, cash stood at $235.0M in the latest year, shareholders' equity was $1.0M, current assets covered current liabilities 2.54 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$1.8B$3.2B$3.1B$3.3B$3.6B$3.8B$3.9B$3.8B$4.0B$3.6B
Current Assets$495.0M$822.0M$775.0M$858.0M$1.2B$1.2B$1.2B$1.1B$1.1B$1.2B
Cash$102.0M$175.0M$139.0M$199.0M$470.0M$513.0M$457.0M$276.0M$246.0M$235.0M
Inventory$217.0M$296.0M$280.0M$316.0M$310.0M$317.0M$325.0M$390.0M$429.0M$493.0M
Receivables$148.0M$252.0M$266.0M$275.0M$226.0M$243.0M$263.0M$259.0M$272.0M$279.0M
Fixed Assets$222.0M$269.0M$300.0M$432.0M$371.0M$396.0M$460.0M$496.0M$550.0M$585.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$2.0M$2.0M$5.0M$3.0M$475.0M$6.0M$567.0M$63.0M$65.0M$41.0M
Other Assets$511.0M$938.0M$926.0M$954.0M$932.0M$1.0B$1.0B$1.1B$1.1B$615.0M
Total Liabilities$968.0M$2.2B$1.7B$1.9B$2.1B$2.1B$2.1B$2.2B$2.5B$2.6B
Current Liabilities$124.0M$349.0M$263.0M$331.0M$401.0M$340.0M$321.0M$307.0M$922.0M$456.0M
Borrowings$665.0M$1.8B$1.4B$1.5B$1.7B$1.7B$1.6B$1.7B$2.0B$2.0B
Other Liabilities$303.0M$408.0M$378.0M$429.0M$445.0M$432.0M$455.0M$512.0M$508.0M$525.0M
Equity$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M
Reserves$840.0M$962.0M$1.4B$1.4B$1.5B$1.7B$1.8B$1.6B$1.5B$1.0B

For Integra LifeSciences Holdings Corporation, operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was negative at $45.0M; free cash flow was positive in 9 of 10 years; financing activities used $19.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$116.0M$115.0M$200.0M$231.0M$204.0M$312.0M$264.0M$140.0M$129.0M$50.0M
Investing Cash Flow−$90.0M−$1.3B−$127.0M−$297.0M−$132.0M−$210.0M−$106.0M−$161.0M−$495.0M−$204.0M
Financing Cash Flow−$4.0M−$21.0M−$42.0M$0−$179.0M−$5.0M−$150.0M−$284.0M−$62.0M−$19.0M
Net Cash Flow$54.0M$73.0M−$36.0M$60.0M$271.0M$43.0M−$57.0M−$180.0M−$30.0M−$11.0M
Free Cash Flow$69.0M$71.0M$122.0M$97.0M$140.0M$264.0M$217.0M$73.0M$25.0M−$45.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.11
EV / EBITDA11.73
FCF Yield9.96%
Quick Ratio2.21
Interest Coverage6.58
Return 1Y15.52%
Return 3Y-65.03%
Return 5Y-80.06%

Integra LifeSciences Holdings Corporation (IART) financials — frequently asked questions

What is Integra LifeSciences Holdings Corporation's annual revenue?

Integra LifeSciences Holdings Corporation (IART) reported annual revenue of $1.6B in its most recent fiscal year.

What is Integra LifeSciences Holdings Corporation's net profit?

Integra LifeSciences Holdings Corporation (IART) reported a net loss of $516.0M in its most recent fiscal year.

What is IART EV/EBITDA?

Integra LifeSciences Holdings Corporation's enterprise value to EBITDA (EV/EBITDA) ratio is 11.73.

Revenue and earnings of other Medical - Devices stocks

ABT revenue $44.3BISRG revenue $10.1BMDT revenue $36.4BSYK revenue $25.1BBSX revenue $20.1BEW revenue $6.1BRMD revenue $5.7BDXCM revenue $4.7BPHG revenue $17.8BZBH revenue $8.2BAll Medical - Devices stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
IART Overview IART Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.